Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Transplant Cell Ther. 2023 Apr 7;29(7):430–437. doi: 10.1016/j.jtct.2023.04.001

Figure 2. TRM (A) and time to CRS/ICANS resolution (A) after anakinra initiation.

Figure 2.

A, cumulative incidence of TRM, defined as the time from anakinra initiation to death with disease progression or relapse as the competing risk.; B, cumulative incidence of CRS/ICANS symptom resolution, whichever happened last, from the time of anakinra initiation with death from any cause as the competing risk Abbreviations: CRS, cytokine release syndrome; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; TRM, treatment-related mortality.